143 related articles for article (PubMed ID: 18827563)
1. Activity of lipoplatin in tumor and in normal cells in vitro.
Arienti C; Tesei A; Ravaioli A; Ratta M; Carloni S; Mangianti S; Ulivi P; Nicoletti S; Amadori D; Zoli W
Anticancer Drugs; 2008 Nov; 19(10):983-90. PubMed ID: 18827563
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
3. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.
Boulikas T
Expert Opin Investig Drugs; 2009 Aug; 18(8):1197-218. PubMed ID: 19604121
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
5. Liposomal cisplatin: a new cisplatin formulation.
Stathopoulos GP
Anticancer Drugs; 2010 Sep; 21(8):732-6. PubMed ID: 20671511
[TBL] [Abstract][Full Text] [Related]
6. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas T; Stathopoulos GP; Volakakis N; Vougiouka M
Anticancer Res; 2005; 25(4):3031-9. PubMed ID: 16080562
[TBL] [Abstract][Full Text] [Related]
7. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts.
Boulikas T
Oncol Rep; 2004 Jul; 12(1):3-12. PubMed ID: 15201951
[TBL] [Abstract][Full Text] [Related]
8. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
[TBL] [Abstract][Full Text] [Related]
11. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
Shang XB; Yu ZT; Tang P; Zhang XZ
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
[TBL] [Abstract][Full Text] [Related]
12. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.
Ronconi L; Giovagnini L; Marzano C; Bettìo F; Graziani R; Pilloni G; Fregona D
Inorg Chem; 2005 Mar; 44(6):1867-81. PubMed ID: 15762713
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
14. In vitro biochemical and pharmacological evaluation of a novel cytotoxic dinuclear platinum(II) complex with 3-amino-5-methyl-5-phenylhydantoin.
Momekov GTs; Ugrinova I; Pasheva EA; Bakalova AG; Varbanov HP; Ferdinandov DV; Ivanov DS; Konstantinov SM
Ann N Y Acad Sci; 2009 Aug; 1171():649-58. PubMed ID: 19723116
[TBL] [Abstract][Full Text] [Related]
15. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
16. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
[TBL] [Abstract][Full Text] [Related]
17. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
18. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
Zisowsky J; Koegel S; Leyers S; Devarakonda K; Kassack MU; Osmak M; Jaehde U
Biochem Pharmacol; 2007 Jan; 73(2):298-307. PubMed ID: 17097621
[TBL] [Abstract][Full Text] [Related]
19. Low renal toxicity of lipoplatin compared to cisplatin in animals.
Devarajan P; Tarabishi R; Mishra J; Ma Q; Kourvetaris A; Vougiouka M; Boulikas T
Anticancer Res; 2004; 24(4):2193-200. PubMed ID: 15330160
[TBL] [Abstract][Full Text] [Related]
20. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
Wang W; Liu G; Zheng J
Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
